AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy

被引：0
作者：
Kagiava, A. [1 ,2 ]
Karaiskos, C. [1 ,2 ]
Lapathitis, G. [1 ,2 ]
Sargiannidou, I. [1 ,2 ]
Bosch, A. [3 ]
Kleopa, K. A. [1 ,2 ,4 ,5 ]
机构：
[1] Cyprus Inst Neurol & Genet, Neurosci Dept, Engomi, Cyprus
[2] Cyprus Sch Mol Med, Engomi, Cyprus
[3] Univ Autonoma Barcelona, Inst Neurosci, Dept Biochem & Mol Biol, Barcelona, Spain
[4] Cyprus Inst Neurol & Genet, Ctr Neuromuscular Disorders, Engomi, Cyprus
[5] Cyprus Sch Mol Med, Engomi, Cyprus
来源：
HUMAN GENE THERAPY | 2021年 / 32卷 / 19-20期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P305
引用
收藏
页码：A121 / A122
页数：2
相关论文
共 50 条
  • [31] Recombinant AAV9 vectors to silence the mutant SOD1 gene in Amyotrophic Lateral Sclerosis
    Biferi, M. G.
    Cohen-Tannoudji, M.
    Roda, M.
    Barkats, M.
    [J]. HUMAN GENE THERAPY, 2013, 24 (12) : A117 - A117
  • [32] Preclinical Gene Therapy with AAV9/SLC6A1 in a Mouse Model of SLC6A1 Related Disorder
    Guo, Weirui
    Shaffo, Frances
    Rioux, Matthew
    Rodriguez, Juan
    Hu, Yuhui
    Gray, Steven J.
    [J]. MOLECULAR THERAPY, 2022, 30 (04) : 80 - 80
  • [33] AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy
    Kagiava, Alexia
    Karaiskos, Christos
    Richter, Jan
    Tryfonos, Christina
    Jennings, Matthew J.
    Heslegrave, Amanda J.
    Sargiannidou, Irene
    Stavrou, Marina
    Zetterberg, Henrik
    Reilly, Mary M.
    Christodoulou, Christina
    Horvath, Rita
    Kleopa, Kleopas A.
    [J]. GENE THERAPY, 2021, 28 (10-11) : 659 - 675
  • [34] AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy
    Alexia Kagiava
    Christos Karaiskos
    Jan Richter
    Christina Tryfonos
    Matthew J. Jennings
    Amanda J. Heslegrave
    Irene Sargiannidou
    Marina Stavrou
    Henrik Zetterberg
    Mary M. Reilly
    Christina Christodoulou
    Rita Horvath
    Kleopas A. Kleopa
    [J]. Gene Therapy, 2021, 28 : 659 - 675
  • [35] Golgi-retained Cx32 mutants interfere with gene addition therapy for CMT1X
    Kyriakoudi, Styliana
    Sargiannidou, Irene
    Kagiava, Alexia
    Olympiou, Margarita
    Kleopa, Kleopas A.
    [J]. HUMAN MOLECULAR GENETICS, 2017, 26 (09) : 1622 - 1633
  • [36] Intravenous Administration of an AAV9 Vector Ubiquitously Expressing C1orf194 Gene Improved CMT-Like Neuropathy in C1orf194-/- Mice
    Shen, Zongrui
    Li, Meiyi
    He, Fei
    Huang, Cheng
    Zheng, Yingchun
    Wang, Zhikui
    Ma, Shunfei
    Chen, Li
    Liu, Zhengshan
    Zheng, Hui
    Xiong, Fu
    [J]. NEUROTHERAPEUTICS, 2023, 20 (06) : 1835 - 1846
  • [37] Intravenous Administration of an AAV9 Vector Ubiquitously Expressing C1orf194 Gene Improved CMT-Like Neuropathy in C1orf194-/- Mice
    Zongrui Shen
    Meiyi Li
    Fei He
    Cheng Huang
    Yingchun Zheng
    Zhikui Wang
    Shunfei Ma
    Li Chen
    Zhengshan Liu
    Hui Zheng
    Fu Xiong
    [J]. Neurotherapeutics, 2023, 20 : 1835 - 1846
  • [38] New Mouse Models of, and AAV9 Gene Therapeutics to Treat, Isolated Methylmalonic Acidemia, Cobalamin B (cblB) Type
    Choi, Eun-Young
    Choi, Karenna
    Li, Lina
    Venditti, Charles P.
    [J]. MOLECULAR THERAPY, 2023, 31 (04) : 67 - 68
  • [39] AAV9-KDAR GENE THERAPY IS A PROMISING TREATMENT APPROACH FOR CMT1B
    Munezero, Daniella
    Paripati, Arun
    Zhu, Jingting
    Chuah, Russell
    Rashnonejad, Afrooz
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024, 29 : S161 - S162
  • [40] AAV9 Intravenous Gene Therapy Enhanced Motor, Cognitive Function and Survival in a Mouse Model of Neuropathic Gaucher Disease
    Lin, Yi
    Kilbane, Brianna
    DeMott, Jacob
    Zhang, Zhenting
    Wang, Xiaohong
    Liou, Benjamin
    Sun, Ying
    Xiao, Weidong
    Pan, Dao
    [J]. MOLECULAR THERAPY, 2019, 27 (04) : 366 - 367
12345